186 related articles for article (PubMed ID: 35089587)
61. Determinants of stability for the E6 protein of papillomavirus type 16.
Liu Y; Cherry JJ; Dineen JV; Androphy EJ; Baleja JD
J Mol Biol; 2009 Mar; 386(4):1123-37. PubMed ID: 19244625
[TBL] [Abstract][Full Text] [Related]
62. Human papillomaviruses and the specificity of PDZ domain targeting.
Pim D; Bergant M; Boon SS; Ganti K; Kranjec C; Massimi P; Subbaiah VK; Thomas M; Tomaić V; Banks L
FEBS J; 2012 Oct; 279(19):3530-3537. PubMed ID: 22805590
[TBL] [Abstract][Full Text] [Related]
63. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation.
Thomas M; Glaunsinger B; Pim D; Javier R; Banks L
Oncogene; 2001 Sep; 20(39):5431-9. PubMed ID: 11571640
[TBL] [Abstract][Full Text] [Related]
64. 1H and 15N resonance assignment, secondary structure and dynamic behaviour of the C-terminal domain of human papillomavirus oncoprotein E6.
Nominé Y; Charbonnier S; Miguet L; Potier N; Van Dorsselaer A; Atkinson RA; Travé G; Kieffer B
J Biomol NMR; 2005 Feb; 31(2):129-41. PubMed ID: 15772752
[TBL] [Abstract][Full Text] [Related]
65. The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein.
Pim D; Tomaic V; Banks L
J Virol; 2009 Oct; 83(19):9863-74. PubMed ID: 19640984
[TBL] [Abstract][Full Text] [Related]
66. The PDZ-Binding Motif of HPV16-E6 Oncoprotein Modulates the Keratinization and Stemness Transcriptional Profile
Cortés-Malagón EM; Palacios-Reyes C; Romero-Cordoba S; Mendoza-Villanueva D; Escobar-Herrera J; Verdejo-Torres O; Contreras RG; Fernádez-Tilapa G; Moreno-Eutimio MA; Moreno J; Hidalgo-Miranda A; Gariglio P; Bonilla-Delgado J
Biomed Res Int; 2017; 2017():7868645. PubMed ID: 29130045
[TBL] [Abstract][Full Text] [Related]
67. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity.
White EA; Kramer RE; Tan MJ; Hayes SD; Harper JW; Howley PM
J Virol; 2012 Dec; 86(24):13174-86. PubMed ID: 23015706
[TBL] [Abstract][Full Text] [Related]
68. PKN binds and phosphorylates human papillomavirus E6 oncoprotein.
Gao Q; Kumar A; Srinivasan S; Singh L; Mukai H; Ono Y; Wazer DE; Band V
J Biol Chem; 2000 May; 275(20):14824-30. PubMed ID: 10809724
[TBL] [Abstract][Full Text] [Related]
69. Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators.
Tomaić V; Gardiol D; Massimi P; Ozbun M; Myers M; Banks L
Oncogene; 2009 Jan; 28(1):1-8. PubMed ID: 18820705
[TBL] [Abstract][Full Text] [Related]
70. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.
Kiyono T; Hiraiwa A; Fujita M; Hayashi Y; Akiyama T; Ishibashi M
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11612-6. PubMed ID: 9326658
[TBL] [Abstract][Full Text] [Related]
71. Chimaeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins.
Pim D; Thomas M; Banks L
Oncogene; 2002 Nov; 21(53):8140-8. PubMed ID: 12444549
[TBL] [Abstract][Full Text] [Related]
72. Structural basis for recognition of the tumor suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus.
Yun HY; Kim MW; Lee HS; Kim W; Shin JH; Kim H; Shin HC; Park H; Oh BH; Kim WK; Bae KH; Lee SC; Lee EW; Ku B; Kim SJ
PLoS Biol; 2019 Jul; 17(7):e3000367. PubMed ID: 31323018
[TBL] [Abstract][Full Text] [Related]
73. Identification of potential binding pocket on viral oncoprotein HPV16 E6: a promising anti-cancer target for small molecule drug discovery.
Kolluru S; Momoh R; Lin L; Mallareddy JR; Krstenansky JL
BMC Mol Cell Biol; 2019 Aug; 20(1):30. PubMed ID: 31387520
[TBL] [Abstract][Full Text] [Related]
74. PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6.
Storrs CH; Silverstein SJ
J Virol; 2007 Apr; 81(8):4080-90. PubMed ID: 17287269
[TBL] [Abstract][Full Text] [Related]
75. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins.
Glaunsinger BA; Lee SS; Thomas M; Banks L; Javier R
Oncogene; 2000 Nov; 19(46):5270-80. PubMed ID: 11077444
[TBL] [Abstract][Full Text] [Related]
76. Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: implications for HPV-tumor diagnosis and therapy.
Illiano E; Demurtas OC; Massa S; Di Bonito P; Consalvi V; Chiaraluce R; Zanotto C; De Giuli Morghen C; Radaelli A; Venuti A; Franconi R
J Transl Med; 2016 Jul; 14(1):224. PubMed ID: 27465494
[TBL] [Abstract][Full Text] [Related]
77. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
78. PDZRN3/LNX3 is a novel target of human papillomavirus type 16 (HPV-16) and HPV-18 E6.
Thomas M; Banks L
J Virol; 2015 Jan; 89(2):1439-44. PubMed ID: 25355882
[TBL] [Abstract][Full Text] [Related]
79. Modulation of microRNA-mRNA Target Pairs by Human Papillomavirus 16 Oncoproteins.
Harden ME; Prasad N; Griffiths A; Munger K
mBio; 2017 Jan; 8(1):. PubMed ID: 28049151
[TBL] [Abstract][Full Text] [Related]
80. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
